Paola Bonetti

Biochemistry, Genetics and Molecular Biology · Life Sciences

23h-index3.8kcitations89works3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Degradation and Inhibitors(24), Hepatitis C virus research(20), Multiple Myeloma Research and Treatments(18), Liver Disease Diagnosis and Treatment(16), Systemic Lupus Erythematosus Research(8)

Publications89 total

Abstract 3157: Novel synthetic lethality-based cellular assays for cancer drug discovery
Cancer Research·2025
Multi-omic lineage tracing predicts the transcriptional, epigenetic and genetic determinants of cancer evolution
Nature Communications·2024· 9 citedOpen Access
Analysis of the strategies involved in the management of epilepsy in the hospital emergency environment
Arquivos de Neuro-Psiquiatria·2024Open Access
Multi-omic lineage tracing predicts the transcriptional, epigenetic and genetic determinants of cancer evolution
2023· 2 citedOpen Access
Supplemental Figures S6 from The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
2023Open Access
Supplemental Table S2-3 from The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
2023Open Access
Supplemental Figures S6 from The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
2023Open Access
Supplemental Table S4 from The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
2023Open Access
Supplemental Table S1 from The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
2023Open Access
Supplemental Figures S7 from The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
2023Open Access
Supplemental Figures S3-5 from The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
2023Open Access
Data from The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
2023Open Access
Supplemental Table S1 from The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
2023Open Access
Data from The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
2023Open Access
Supplemental Figures S3-5 from The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
2023Open Access
Supplemental Table S4 from The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
2023Open Access
Supplemental Figures S7 from The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
2023Open Access
Supplemental Figures S1-2 from The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
2023Open Access
Supplemental Figures S1-2 from The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
2023Open Access
Supplemental Table S2-3 from The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
2023Open Access
page 1 of 5Next →

Frequent Co-authors

G. Diodati(13), A. Albertí(12), C. Casarin(11), Maurilio Ponzoni(11), Emanuele Zucca(11), Francesco Bertoni(11), Giorgio Inghirami(10), G. Realdi(9), Michela Boi(9), Francesco Nicassio(9), Ivo Kwee(8), Andrea Rinaldi(8), Anastasios Stathis(7), Pier Giuseppe Pelicci(7), Liliana Chemello(7), Patrizia Pontisso(7), A. Ruol(7), Monica Testoni(6), Matteo Jacopo Marzi(6), F. Tremolada(5)